Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20200046 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MEN1POLBKMT2ASIGMAR1 | |
| SCHEMBL22069474 | 0.84 | KMT2A (0.39) | ALDH1A1MEN1POLBKMT2ASIGMAR1 | |
| SCHEMBL30741640 | 0.83 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL24186639 | 0.83 | ALDH1A1 (0.34) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL22069454 | 0.82 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL22069453 | 0.81 | NPSR1 (0.31) | MEN1KMT2A | |
| SCHEMBL21313109 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL30741641 | 0.80 | ALDH1A1 (0.36) | ALDH1A1SIGMAR1LMNA | |
| SCHEMBL22403271 | 0.80 | ALDH1A1 (0.32) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL30741642 | 0.79 | HSD17B10 (0.36) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | claimed |
| EP-3544964-B1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma AG (DE) | 2020-06-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | ALDH1A1 4666/4885MEN1 89/4885POLB 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.